|
Staging of Supratentorial Primitive Neuroectodermal Tumors
Current Clinical Trials
Patients with supratentorial primitive neuroectodermal tumors (SPNET) are staged in a fashion similar to that used for children with medulloblastoma. SPNET may be disseminated at the time of diagnosis, although the incidence of dissemination may be somewhat less than that of medulloblastomas or pineoblastomas, with dissemination at diagnosis being documented in approximately 10% to 20% of patients.[1,2] SPNET are often amenable to resection; in series, 50% to 60% of patients were totally or near-totally resected.[1,2]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with childhood supratentorial primitive neuroectodermal tumor. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Cohen BH, Zeltzer PM, Boyett JM, et al.: Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 13 (7): 1687-96, 1995.
[PUBMED Abstract]
-
Reddy AT, Janss AJ, Phillips PC, et al.: Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88 (9): 2189-93, 2000.
[PUBMED Abstract]
 Back to Top
< Previous Section | Next Section > |
